|
1
|
Zhou Q, Zhou CC, Chen GY, et al: A
multicenter phase II study of sorafenib monotherapy in clinically
selected patients with advanced lung adenocarcinoma after failure
of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).
Lung Cancer. 83:369–373. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang Z, Zhang X, Bai H, et al: EML4-ALK
rearrangement and its clinical significance in Chinese patients
with advanced non-small cell lung cancer. Oncology. 83:248–256.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Soda M, Choi YL, Enomoto M, et al:
Identification of the transforming EML4-ALK fusion gene in
non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Inamura K, Takeuchi K, Togashi Y, et al:
EML4-ALK fusion is linked to histological characteristics in a
subset of lung cancers. J Thorac Oncol. 3:13–17. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Koivunen JP, Mermel C, Zejnullahu K, et
al: EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in
lung cancer. Clin Cancer Res. 14:4275–4283. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang J, Zhang X, Su J, et al: Concomitant
EGFR mutation and EML4-ALK gene fusion in non-small cell lung
cancer. J Clin Oncol. 29(Suppl): [abstr 10517]. 2011.
|
|
7
|
Zhang X, Zhang S, Yang X, et al: Fusion of
EML4 and ALK is associated with development of lung adenocarcinomas
lacking EGFR and KRAS mutations and is correlated with ALK
expression. Mol Cancer. 9:1882010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kuo YW, Wu SG, Ho CC, et al: Good response
to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK
fusion gene and EGFR mutation. J Thorac Oncol. 5:2039–2040. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tiseo M, Gelsomino F, Boggiani D, et al:
EGFR and EML4-ALK gene mutations in NSCLC: A case report of
erlotinib-resistant patient with both concomitant mutations. Lung
Cancer. 71:241–243. 2011. View Article : Google Scholar
|
|
10
|
Popat S, Vieira de Araújo A, Min T, et al:
Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK
rearrangement responding to erlotinib. J Thorac Oncol. 6:1962–1963.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tanaka H, Hayashi A, Morimoto T, et al: A
case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK
fusion gene. BMC Cancer. 12:5582012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Santelmo C, Ravaioli A, Barzotti E, et al:
Coexistence of EGFR mutation and ALK translocation in NSCLC:
Literature review and case report of response to gefitinib. Lung
Cancer. 81:294–296. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen X, Zhang J, Hu Q, et al: A case of
lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK
fusion gene. Lung Cancer. 81:308–310. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shigematsu H, Lin L, Takahashi T, et al:
Clinical and biological features associated with epidermal growth
factor receptor gene mutations in lung cancers. J Natl Cancer Inst.
97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kosaka T, Yatabe Y, Endoh H, et al:
Mutations of the epidermal growth factor receptor gene in lung
cancer: Biological and clinical implications. Cancer Res.
64:8919–8923. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li Y, Li Y, Yang T, et al: Clinical
significance of EML4-ALK fusion gene and association with EGFR and
KRAS gene mutations in 208 Chinese patients with non-small cell
lung cancer. PLoS One. 8:e520932013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gazdar AF, Shigematsu H, Herz J, et al:
Mutations and addiction to EGFR: The Achilles 'heal' of lung
cancers? Trends Mol Med. 10:481–486. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Inamura K, Takeuchi K, Togashi Y, et al:
EML4-ALK lung cancers are characterized by rare other mutations, a
TTF-1 cell lineage, an acinar histology and young onset. Mod
Pathol. 22:508–515. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Martelli MP, Sozzi G, Hernandez L, et al:
EML4-ALK rearrangement in non-small cell lung cancer and non-tumor
lung tissues. Am J Pathol. 174:661–670. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shaw AT, Yeap BY, Mino-Kenudson M, et al:
Clinical features and outcome of patients with non-small-cell lung
cancer who harbor EML4-ALK. J Clin Oncol. 27:4247–4253. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wong DW, Leung EL, So KK, et al: The
EML4-ALK fusion gene is involved in various histologic types of
lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer.
115:1723–1733. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Takahashi T, Sonobe M, Kobayashi M, et al:
Clinicopathologic features of non-small-cell lung cancer with
EML4-ALK fusion gene. Ann Surg Oncol. 17:889–897. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takeda M, Okamoto I, Sakai K, et al:
Clinical outcome for EML4-ALK-positive patients with advanced
non-small-cell lung cancer treated with first-line platinum-based
chemotherapy. Ann Oncol. 23:2931–2936. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, et al: Gefitinib or
carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med.
361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zornosa C, Vandergrift JL, Kalemkerian GP,
et al: First-line systemic therapy practice patterns and
concordance with NCCN guidelines for patients diagnosed with
metastatic NSCLC treated at NCCN institutions. J Natl Compr Canc
Netw. 10:847–856. 2012.PubMed/NCBI
|
|
26
|
Camidge DR, Bang YJ, Kwak EL, et al:
Activity and safety of crizotinib in patients with ALK-positive
non-small-cell lung cancer:updated results from a phase I study.
Lancet Oncol. 13:1011–1019. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sasaki T, Rodig SJ, Chirieac LR and Jänne
PA: The biology and treatment of EML4-ALK non-small cell lung
cancer. Eur J Cancer. 46:1773–1780. 2010. View Article : Google Scholar : PubMed/NCBI
|
